ASSEMBLY BIOSCIENCES, INC.(ASMB)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ASSEMBLY BIOSCIENCES, INC. (ASMB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASMB at 41.5/100 on a 32-signal composite quality model, placing it at rank #2,058 of 2,962 stocks — the bottom half of the AI-ranked universe. ASMB scores in the top quartile across revenue growth (92.3), institutional flow (84.4). Areas of concern include earnings quality (1.3) and free cash flow (6.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ASSEMBLY BIOSCIENCES, INC. reports quarterly revenue of $13.4M, net income of $-3.9M, free cash flow of $-15.5M. Top institutional holders of ASMB by reported 13-F value include GILEAD SCIENCES, FARALLON CAPITAL MANAGEMENT, Paradigm Biocapital Advisors, based on the most recent SEC filings. ASMB trades on the Nasdaq exchange and files with the SEC under CIK 1426800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ASSEMBLY BIOSCIENCES, INC. directly from SEC EDGAR.